Search: onr:"swepub:oai:gup.ub.gu.se/306905" >
Patient-derived sca...
-
Gustafsson, AnnaGothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Department of Laboratory Medicine
(author)
Patient-derived scaffolds as a drug-testing platform for endocrine therapies in breast cancer
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
2021-06-25
-
Springer Science and Business Media LLC,2021
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/306905
-
https://gup.ub.gu.se/publication/306905URI
-
https://doi.org/10.1038/s41598-021-92724-9DOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Three-dimensional cell culture platforms based on decellularised patient-based microenvironments provide in vivo-like growth conditions allowing cancer cells to interact with intact structures and components of the surrounding tissue. A patient-derived scaffold (PDS) model was therefore evaluated as a testing platform for the endocrine therapies (Z)-4-Hydroxytamoxifen (4OHT) and fulvestrant as well as the CDK4/6-inhibitor palbociclib, monitoring the treatment responses in breast cancer cell lines MCF7 and T47D adapted to the patient-based microenvironments. MCF7 cells growing in PDSs showed increased resistance to 4OHT and fulvestrant treatment (100- and 20-fold) compared to 2D cultures. Quantitative PCR analyses of endocrine treated cancer cells in PDSs revealed upregulation of pluripotency markers further supported by increased self-renewal capacity in sphere formation assays. When comparing different 3D growth platforms including PDS, matrigel, gelatin sponges and 3D-printed hydrogels, 3D based cultures showed slightly varying responses to fulvestrant and palbociclib whereas PDS and matrigel cultures showed more similar gene expression profiles for 4OHT treatment compared to the other platforms. The results support that the PDS technique maximized to provide a multitude of smaller functional PDS replicates from each primary breast cancer, is an up-scalable patient-derived drug-testing platform available for gene expression profiling and downstream functional assays.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Garre, Elena,1978Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Department of Laboratory Medicine(Swepub:gu)xgarre
(author)
-
Leiva, Maria CarmenGothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Department of Laboratory Medicine(Swepub:gu)xdelcm
(author)
-
Salerno, SimonaGothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Department of Laboratory Medicine(Swepub:gu)xsales
(author)
-
Ståhlberg, Anders,1975Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Wallenberg Centre for Molecular and Translational Medicine,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Sahlgrenska Center for Cancer Research (SCCR),Department of Laboratory Medicine(Swepub:gu)xsandw
(author)
-
Landberg, Göran,1963Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för laboratoriemedicin,Department of Laboratory Medicine(Swepub:gu)xlgora
(author)
-
Göteborgs universitetInstitutionen för biomedicin, avdelningen för laboratoriemedicin
(creator_code:org_t)
Related titles
-
In:Scientific Reports: Springer Science and Business Media LLC11:12045-2322
Internet link
Find in a library
To the university's database